Please login to the form below

Not currently logged in
Email:
Password:

Frances Heller joins BMS senior management

Takes up business development role and will report to Lamberto Andreotti

Bristol-Myers Squibb has appointed Frances Heller as senior vice president, business development.

Reporting to the pharma company's CEO Lamberto Andreotti, she will also sit on the BMS senior management team.

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

Prior to that she served as head of strategic alliances at Novartis and before that as corporate and intellectual property counsel for Celera Genomics.

“With broad experience across both the biotech and pharmaceutical industries, I believe Fran will be an important addition to my diverse management team and to the company,” said Andreotti.

“In addition, her scientific, business and legal background, as well as her experience across therapeutic areas, will help Bristol-Myers Squibb continue to execute its strategy of finding external innovation that complements our own internal R&D pipeline and helps us bring important new medicines to patients.”

2nd October 2012

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics